This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Consultations

Performance Agreement to Control, Monitor and Minimize the Release of Decabromodiphenyl Ether Commercial Mixture (DecaBDE) from Canadian Facilities Where DecaBDE Is Used or Handled

Full text of the proposed agreement (HTML) (PDF; 216 KB)

Environment Canada and Health Canada, in collaboration with the Bromine Science and Environmental Forum and participating companies, are pleased to provide the following proposed Performance Agreement on DecaBDE for a 60-day public consultation period.

Following the addition of polybrominated diphenyl ethers (PBDEs) to the List of Toxic Substances in Schedule 1 of the Canadian Environmental Protection Act, 1999 (CEPA 1999), the Government of Canada published a Risk Management Strategy for PBDEs in September 2006. The current risk management objective for decaBDE1 outlined in the Strategy is to prevent the introduction of its manufacture in Canada, and to minimize its releases into the environment from all sources in Canada. Progress towards this risk management objective is being achieved by:

  1. The Polybrominated Diphenyl Ether Regulations (PBDE Regulations), which were published on July 9, 2008. These regulations prohibit the manufacture of decaBDE and eliminate the manufacture, import, use or sale of tetra-, penta- and hexaBDEs.
  2. The proposed Performance Agreement aims to manage and reduce releases of DecaBDE from its use in plastic and textile manufacturing facilities by setting numerical performance objectives for releases of DecaBDE to the environment for each sector. These objectives are met through the implementation of a code of practice at each participating facility, the measurement of baseline environmental releases of DecaBDE, and the annual reporting of uses and releases of DecaBDE at those facilities, and;
  3. Other risk management tools and measures currently under development, such as:
    1. a regulation to control PBDEs in domestic and imported manufactured products (consultation period anticipated for 2009);
    2. a State of the Science report on decaBDE, which is a review of newly published science on decaBDE, in order to determine whether further controls on decaBDE are warranted (anticipated for publication in early 2009);
    3. a management strategy for PBDE-containing products at end-of-life, and;
    4. monitoring Canadians’ exposure to PBDEs and concentrations in the environment (ongoing).

Environment Canada invites all interested parties to provide their comments on the proposed Performance Agreement. All written comments will be reviewed and taken into consideration during the finalization of the Agreement.

Please forward your written comments, by May 28, 2009, to EPA_EPE@ec.gc.ca.
Please include "Consultation on Proposed Performance Agreement on DecaBDE" in the subject line of your email message. You may also send your comments by mail to Mr. Abdoulaye Traore and contact him for more information at:

Abdoulaye Traore
Chemicals Management Division
351 St. Joseph Boulevard, 17th floor
Gatineau, QC K1A 0H3
Tel.: 819-994-9328

For more information on PBDEs, please consult the Management of Toxic Substances website.


1 The typical composition of the commercial mixture referred to as “DecaBDE supplied in Canada is composed of approximately 97% decabromodiphenyl ether (decaBDE) and up to 3% of other brominated diphenyl ethers. The commercial mixture is capitalized to distinguish it from the congeners it contains (i.e. "DecaBDE" vs. "decaBDE").

Agreement Details

Full Text of the Agreement

Date modified: